1 All‐cause mortality |
3 |
60 |
Risk Difference (M‐H, Fixed, 95% CI) |
0.0 [‐0.11, 0.11] |
2 Liver morbidity |
3 |
60 |
Risk Difference (M‐H, Fixed, 95% CI) |
0.0 [‐0.11, 0.11] |
3 Adverse events |
3 |
60 |
Risk Ratio (M‐H, Fixed, 95% CI) |
5.4 [0.69, 42.32] |
4 Pruritus |
2 |
38 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.12 [0.50, 2.53] |
5 Serum alkaline phosphatases (U/L) |
4 |
79 |
Mean Difference (IV, Fixed, 95% CI) |
‐186.04 [‐249.03, ‐123.04] |
5.1 Duration of administration 6 months |
2 |
38 |
Mean Difference (IV, Fixed, 95% CI) |
‐141.97 [‐228.30, ‐55.64] |
5.2 Duration of administration 12‐13 months |
2 |
41 |
Mean Difference (IV, Fixed, 95% CI) |
‐236.23 [‐328.35, ‐144.10] |
6 Serum gamma‐glutamyltransferase (U/L) |
4 |
79 |
Mean Difference (IV, Fixed, 95% CI) |
‐1.22 [‐11.97, 9.52] |
6.1 Duration of administration 6 months |
2 |
38 |
Mean Difference (IV, Fixed, 95% CI) |
‐1.23 [‐12.17, 9.72] |
6.2 Duration of administration 12‐13 months |
2 |
41 |
Mean Difference (IV, Fixed, 95% CI) |
‐1.20 [‐56.79, 54.39] |
7 Serum alanine aminotransferase (U/L) |
2 |
35 |
Mean Difference (IV, Fixed, 95% CI) |
‐5.61 [‐24.50, 13.27] |
8 Plasma immunoglobulin M (mg/dl) |
3 |
50 |
Mean Difference (IV, Fixed, 95% CI) |
‐164.00 [‐259.47, ‐68.53] |
9 Total cholesterol (mg/dl) |
2 |
38 |
Mean Difference (IV, Fixed, 95% CI) |
‐12.51 [‐32.65, 7.64] |
10 Triglycerides (mg/dl) |
2 |
38 |
Mean Difference (IV, Fixed, 95% CI) |
‐20.12 [‐47.73, 7.49] |
11 Serum bilirubin (mg/dl) |
2 |
34 |
Mean Difference (IV, Fixed, 95% CI) |
‐0.19 [‐0.38, ‐0.00] |
12 Number of patients having bezafibrate withdrawn due to adverse events |
3 |
60 |
Risk Difference (M‐H, Fixed, 95% CI) |
0.03 [‐0.09, 0.16] |